MusclePharm Corp
Form SC 13D
July 01, 2015

T	IN	J	ľТ	\mathbf{E}	\Box	9	T	Δ	П	וי	\Box	7
ι	JI.	N		\mathbf{C}	IJ		1 (м				7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

MUSCLEPHARM CORP.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

627335201

(CUSIP Number)

Wynnefield Partners Small Cap Value, L.P. I

450 Seventh Avenue, Suite 509

New York, New York 10123

Attention: Mr. Nelson Obus

Copy to:

Jeffrey S. Tullman, Esq.

Kane Kessler, P.C.

1350 Avenue of the Americas, 26th Floor

New York, New York 10019

(212) 541-6222

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 25, 2015

(Date of Event which requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box "

```
CUSIP No. 627335201
```

13DPage 2 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Partners Small Cap Value, L.P. I 13-3953291
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 WC
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 Delaware
                SOLE VOTING POWER
NUMBER OF
SHARES
              7
BENEFICIALLY 271,668
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

EACH 0 (See Item 5) SOLE DISPOSITIVE POWER REPORTING 9 **PERSON** 271,668 (See Item 5) WITH **10 SHARED DISPOSITIVE POWER** 0 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 271,668 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 2% TYPE OF REPORTING PERSON* 14

PN

```
CUSIP No. 627335201
```

13DPage 3 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Partners Small Cap Value, L.P. 13-3688497
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 WC
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 Delaware
                SOLE VOTING POWER
NUMBER OF
SHARES
              7
BENEFICIALLY 178,833
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

EACH 0 (See Item 5) SOLE DISPOSITIVE POWER REPORTING 9 **PERSON** 178,833 (See Item 5) WITH **10 SHARED DISPOSITIVE POWER** 0 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 178,833 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 1.3% TYPE OF REPORTING PERSON* 14

PN

```
CUSIP No. 627335201
```

13DPage 4 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Small Cap Value Offshore Fund, Ltd. (No IRS Identification No.)
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 WC
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 Cayman Islands
                SOLE VOTING POWER
NUMBER OF
SHARES
              7
BENEFICIALLY 199,499
                                (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

EACH 0 (See Item 5) SOLE DISPOSITIVE POWER REPORTING 9 **PERSON** 199,499 (See Item 5) WITH **10 SHARED DISPOSITIVE POWER** 0 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 199,499 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* **12** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 1.5% TYPE OF REPORTING PERSON* 14

CO

```
CUSIP No. 627335201
```

13DPage 5 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Capital, Inc. Profit Sharing Plan
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 N/A
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 Delaware
                SOLE VOTING POWER
NUMBER OF
SHARES
              7
BENEFICIALLY 40,000
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

EACH 0 (See Item 5) SOLE DISPOSITIVE POWER REPORTING 9 **PERSON** 40,000 (See Item 5) WITH **10 SHARED DISPOSITIVE POWER** 0 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 40,000 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 0.3% TYPE OF REPORTING PERSON* 14

CO

```
CUSIP No. 627335201
```

13DPage 6 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Capital Management, LLC 13-4018186
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 N/A
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 New York
NUMBER OF
                SOLE VOTING POWER
SHARES
              7
BENEFICIALLY 450,501
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

```
EACH
```

REPORTING 0 (See Item 5) SOLE DISPOSITIVE POWER

PERSON

9

WITH

450,501 (See Item 5) **10** SHARED DISPOSITIVE POWER

0 (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11

450,501 (See Item 5)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* $\bf 12$

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13

3.3%

TYPE OF REPORTING PERSON*

14

OO

```
CUSIP No. 627335201
```

13DPage 7 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Wynnefield Capital, Inc. 13-3688495
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 N/A
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 Delaware
NUMBER OF
                SOLE VOTING POWER
SHARES
              7
BENEFICIALLY 199,499
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

```
EACH
```

REPORTING 0 (See Item 5) SOLE DISPOSITIVE POWER

PERSON

9

WITH

199,499 (See Item 5) **10**SHARED DISPOSITIVE POWER

0 (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11

199,499 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13

1.5% TYPE OF REPORTING PERSON*

14

CO

```
CUSIP No. 627335201
```

13DPage 8 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Nelson Obus
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 N/A
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 United States
NUMBER OF
                SOLE VOTING POWER
SHARES
          7
BENEFICIALLY 40,000
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

```
EACH
```

REPORTING 650,000 (See Item 5) SOLE DISPOSITIVE POWER

PERSON

9

WITH

40,000 (See Item 5) **10** SHARED DISPOSITIVE POWER

650,000 (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11

690,000 (See Item 5)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* $\bf 12$

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) ${f 13}$

TYPE OF REPORTING PERSON*

14

IN

5.1%

```
CUSIP No. 627335201
```

13DPage 9 of 14

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1
 Joshua Landes
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) "
2
 (b) x
 SEC USE ONLY
3
 SOURCE OF FUNDS*
4
 N/A
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or
 2(e)
5
 CITIZENSHIP OR PLACE OF ORGANIZATION
6
 United States
NUMBER OF
                SOLE VOTING POWER
SHARES
          7
BENEFICIALLY 0
                               (See Item 5)
              8 SHARED VOTING POWER
OWNED BY
```

```
EACH
```

REPORTING 650,000 (See Item 5) SOLE DISPOSITIVE POWER

PERSON

9

WITH

0 (See Item 5) **10 SHARED DISPOSITIVE POWER**

650,000 (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11

(See Item 5) 650,000

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* **12**

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13

5% TYPE OF REPORTING PERSON*

14

IN

CUSIP No. 627335201

13DPage 10 of 14

Item 1. Security and Issuer.

This Statement of Beneficial Ownership on Schedule 13D (the "Schedule 13D") relates to the shares of common stock, \$0.001 par value per share (the "Common Stock") of MusclePharm Corp., a Nevada corporation (the "Issuer"). The Issuer maintains its principal executive office at 4721 Ironton Street, Building A, Denver, Colorado 80239.

Item 2. Identity and Background.

This Schedule 13D is filed by the Wynnefield Reporting Persons.

(a), (b), (c) and (f). The "Wynnefield Reporting Persons" are Wynnefield Partners Small Cap Value, L.P. I ("Wynnefield Partners I"), Wynnefield Partners Small Cap Value, L.P. ("Wynnefield Partners"), Wynnefield Small Cap Value Offshore Fund, Ltd. ("Wynnefield Offshore"), Wynnefield Capital, Inc. Profit Sharing Plan ("Plan"), Wynnefield Capital Management, LLC ("WCM"), Wynnefield Capital, Inc. ("WCI"), Nelson Obus and Joshua H. Landes. The Wynnefield Reporting Persons that are entities, are each separate and distinct entities with different beneficial owners (whether designated as limited partners or stockholders).

WCM, a New York limited liability company, is the general partner of Wynnefield Partners I and Wynnefield Partners, each a private investment company organized as limited partnerships under the laws of the State of Delaware. Nelson Obus and Joshua H. Landes are the managing members of WCM and the principal executive officers of WCI, the investment manager of Wynnefield Offshore, a private investment company organized under the laws of the Cayman Islands. The Plan is an employee profit sharing plan organized under the laws of the State of Delaware. Mr. Obus is the portfolio manager of the Plan. Messrs. Obus and Landes are citizens of the United States of America.

Messrs. Obus and Landes are citizens of the United States of America.

The business address of the Wynnefield Reporting Persons is 450 Seventh Avenue, Suite 509, New York, New York 10123.

(d) and (e). During the last five years, none of the Wynnefield Reporting Persons had been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

The securities reported in this Schedule 13D as directly beneficially owned by the Wynnefield Reporting Persons were acquired with funds of approximately \$6,277,163 (including brokerage commissions). All such funds were provided from the working capital or personal funds of the Wynnefield Reporting Persons who directly beneficially own such securities.

CUSIP No. 627335201

13DPage 11 of 14

Item 4. Purpose of the Transaction

This Schedule 13D is filed by the Wynnefield Reporting Person to report acquisitions of shares of the Common Stock as a result of which the Wynnefield Reporting Person may be deemed to be the beneficial owner (as such term is defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of more than 5% of the outstanding shares of the Common Stock of the Issuer. Other than as set forth in this Item 4, the Wynnefield Reporting Persons do not have any current plans, proposals or negotiations that relate to or would result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Wynnefield Reporting Persons intend to review their investment in the Issuer on a continuing basis, and to the extent permitted by law, may seek to engage in discussions with other stockholders and/or with management and the Board of the Issuer concerning the business, operations or future plans of the Issuer. Depending on various factors including, without limitation, the Issuer's financial position, the price levels of the shares of Common Stock, conditions in the securities markets and general economic and industry conditions, the